Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 21, Issue 5, 1999, Pages 362-370

  Margolis, David ^a,b   Heredia, Alonso ^a   Gaywee, Jariyanart ^b   Oldach, David ^a,b   Drusano, George ^c   Redfield, Robert ^a,b  

^a INSTITUTE OF HUMAN VIROLOGY   (United States)

^b Dept of Microbiology and Immunology ^*  (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Abacavir; Antiproliferative; Antiretroviral; HIV 1; Mycophenolic acid; Synergy

Indexed keywords

ABACAVIR; GUANOSINE PHOSPHATE; INOSINE PHOSPHATE; MYCOPHENOLIC ACID; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONONUCLEAR CELL; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; RETROVIRUS; VIRUS REPLICATION;

EID: 0032841022     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199908150-00002     Document Type: Article

References (43)

1. Blanchi V, Borella S, Calderazzo F, Ferraro P, Chieco Bianchi L, Reichard P. Inhibition of ribonucleotide reductase by 2′-substituted deoxycytidine analogs: possible application in AIDS treatment. Proc Natl Acad Sci USA 1994;91:8403-7.
2. Meyerhans A, Vartanian JP, Hultgren C, et al. Restriction and enhancement of human immunodeficiency virus type 1 replication by modulation of intracellular deoxynucleoside triphosphate pools. J Virol 1994;68:535-40.
3. Gao WY, Cara A, Gallo RC, Lori F. Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication. Proc Natl Acad Sci USA 1993;90:8925-8.
4. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994; 266:801-5.
5. Gao WY, Johns DG, Mitsuya H. Anti-human immunodeficiency virus type 1 activity of hydroxyurea in combination with 2′,3′-dideoxynucleosides. Mol Pharmacol 1994;46:767-72.
6. Malley SD, Grange JM, Hamedi-Sangsari F, Vila JR. Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2′,3′-dideoxyinosine in infected resting human lymphocytes. Proc Natl Acad Sci USA 1994;91:11017-21.
7. Gao WY, Johns DG, Chokekuchai S, Mitsuya H. Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2′,3′-dideoxynucleoside activities against replication of human immunodeficiency virus. Proc Natl Acad Sci USA 1995;92:8333-7.
8. Lori F, Malykh AG, Foli A, et al. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Res Hum Retroviruses 1997;13:1403-9.
9. Luzzati R, Di Perri G, Fendt D, Ramarli D, Broccali G, Concia E. Pharmacokinetics, safety and anti-human immunodeficiency virus (HIV) activity of hydroxyurea in combination with didanosine. J Antimicrob Chemother 1998;42:565-6.
10. Biron F, Lucht F, Peyramond D, et al. Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 1995;10: 36-40.
11. Biron F, Lucht F, Peyramond D, et al. Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals. Antiviral Res 1996;29:111-3.
12. Montaner JS, Zala C, Conway B, et al. A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080. J Infect Dis 1997;175:801-6.
13. Vila J, Biron F, Nugier F, Vallet T, Peyramond D. 1-year follow-up of the use of hydroxycarbamide and didanosine in HIV infection. Lancet 1996;348:203-4.
14. Giacca M, Zanussi S, Comar M, et al. Treatment of human immunodeficiency virus infection with hydroxyurea: virologie and clinical evaluation. J Infect Dis 1996;174:204-9.
15. Rutschmann OT, Opravil M, Iten A, et al. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study. AIDS 1998;12: F71-7.
16. Johns DG, Gao WY. Selective depletion of DNA precursors: an evolving strategy for potentiation of dideoxynucleoside activity against human immunodeficiency virus. Biochem Pharmacol 1998;55:1551-6.
17. De Boer RJ, Boucher CA, Perelson AS. Target cell availability and the successful suppression of HIV by hydroxyurea and didanosine. AIDS 1998;12:1567-70.
18. Staszeweski S, Keiser P, Gathe J, et al. Ziagen/combivir is equivalent to indinavir/combivir in antiretroviral therapy naive adults at 24 weeks [abstract 20]. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999.
19. Allison AC, Almquist SJ, Muller CD, Eugui EM. In vitro immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443. Transplant Proc 1991;23(Suppl 2): 10-4.
20. Allison AC, Kowalski WJ, Muller CD, Eugui EM. Mechanisms of action of mycophenolic acid. Ann NY Acad Sci 1993;696:63-87.
21. Carr SF, Papp E, Wu JC, Natsumeda Y. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 1993;268: 27286-90.
22. Ichimura H, Levy JA. Polymerase substrate depletion: a novel strategy for inhibiting the replication of the human immunodeficiency virus. Virology 1995;211:554-60.
23. Neyts J, Andrei G, De Clercq E. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob Agents Chemother 1998;42:216-22.
24. Neyts J, Andrei G, De Clercq E. The antiherpesvirus activity of H2G is markedly enhanced by the novel immunosuppressive agent mycophenolate mofetil. Antimicrob Agents Chemother 1998;42: 3285-9.
25. Popovic M, Sarngadharan MG, Read E, Gallo RC. Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre AIDS. Science 1984; 224:497.
26. Chenge-Mayer C, Levy JA. Distinct biological and serological properties of human immunodeficiency viruses from the brain. Ann Neurol 1988;23:S58.
27. Schinazy RF, Lloyd RM Jr, Nguyen MH, et al. Characterization of human immunodeficiency viruses resistant to oxathiolance-cytosine nucleosides. Antimicrob Agents Chemother 1993;37:875.
28. ACTG virology manual, NIH Pub No. 94 3828. Bethesda, MD: National Institutes of Health, 1994.
29. Harada S, Koyanagi Y, Yamamoto N. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in plaque assay. Science 1985;229:563.
30. Perno C.-F, Yarchoan R. Culture of HIV in monocytes and macrophages. Current Protocols in Immunology 1993(Suppl 5):12.4.4-5.
31. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev 1995; 47:331-85.
32. D'Argenio DZ, Schumitzky A. ADAPT H: a program package for simulation identification and optimal experimental design. Los Angeles: Biomedical Simulations Resource, University of Southern California, Los Angeles, 1990.
33. Ziagen package insert. Research Triangle Park, NC: Glaxo Wellcome, Inc., 1999.
34. Cellcept package insert. Nutley, NJ: Roche Laboratories, 1998.
35. Bullingham RES, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc 1996;28:925-9.
36. Drusano GL, D'Argenio DZ, Symonds W, et al. Nucleoside analog 1592U89 and human immunodeficiency virus protease inhibitor 141W94 are synergistic in vitro. Antimicrob Agents Chemother 1998;42:2153-9.
37. Tisdale M, Alnadaf T, Cousens D. Combination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89. Antimicrob Agents Chemother 1997;41:1094-8.
38. Lanier R, Ait-Khaled M, Madison S, et al. Analysis of possible predictors of response to abacavir (ABC) in antiretroviral-experienced adults; comparison of viral genotype, viral phenotype and patient treatment history [abstract 134]. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999.
39. Vogt M W, Hartshorrn KL, Furman PA, et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science 1987;235:1376-9.
40. Baba M, Pauwels R, Balzarini J, Herdewijn P, DeClercq E, Desmyter J. Ribavirin antagonizes inhibitory effects of purine 2′,3′-dideoxynucleosides on replication of human immunodeficiency vi-rus in vitro. Antimicrob Agents Chemother 1987;31:1613-17.
41. Hartman NR, Ahluwalia GS, Cooney DA, et al. Inhibitors of IMP dehydrogenase stimulate the phosphorylation of the anti-human immunodeficiency virus nucleosides 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine. Mol Pharmacol 1991;40:118-24.
42. + counts >400 cells/μI and plasma HIV-1 RNA >5000 copies/mL [abstract 610]. Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, 1999.
43. Dayton JS, Turka LA, Thompson CB, Mitchell BS. Comparison of the effects of mizoribine with those of azathioprine, 6-mercaptopurine, and mycophenolic acid on T-lymphocyte proliferation and purine ribonucleotide metabolism. Mol Pharmacol 1994;41:671-676.